Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...

Hims & Hers Health, Inc.'s core growth and product diversification signal long-term potential, despite short-term dips. Click ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

Explore how GLP-1a drugs transform the food industry from a threat to an opportunity. Our 36-page strategy briefing outlines the potential for growth by meeting the rising demand for protein, fiber, ...

Ali Eastburn missed her son’s rehearsal dinner — and nearly missed the wedding — when her appendix burst while traveling, ...

Innovent Biologics receives US FDA clearance to initiate phase 1 clinical trial of novel oral GLP-1R agonist, IBI3032: San Francisco Wednesday, August 6, 2025, 14:00 Hrs [IST] Inn ...

Dr. Tim Church predicted recently that GLP-1 agonists, GLP-1 /GIP agonists and similar prescription drugs will soon be as ...

Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.

Investors must now underwrite opportunities with a “financing risk first” mindset, says Siddhi Capital cofounder Steven Finn.

As consumer interest in metabolic health, gut support and clean-label products accelerates, dietary fiber, like carob, ...